Obsidian Therapeutics Inc. Common Stock (OBX)
Stock · NASDAQ · Health Care
$11.77as of 10/16/2026
Price chart
Active signals
High Beta100.0%
RSI Positive Divergence21.4%Resistance level
$12.99
Industry
Biotechnology: Pharmaceutical Preparations
About OBX
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate pr…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 87
- Website
- obsidiantx.com
Fundamentals
- 1-day range
- $12.06$12.67
- Market cap
- $22.74M
- P/E (trailing)
- —
- P/E (forward)
- -5.73
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 5.85
- Avg. volume
- 367.9K
52-week range
$11.79$49.97
Obsidian Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucelbenzinga · 10/2/2026
- Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual MeetingYahoo · 10/2/2026
- Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene AutoleucelBenzinga · 10/2/2026
- Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32Benzinga · 9/22/2026
- Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For ErrorSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →Acquired
225.9K
Disposed
0
- Hagen Heidi · August 3, 2026 · Grant37.7K
- Fardis Maria · August 3, 2026 · Grant37.7K
- Peter Barrett · August 3, 2026 · Grant37.7K
- Jagasia Madan · August 3, 2026 · Grant37.7K
- Norkunas Matthew · August 3, 2026 · Grant37.7K
- ROSS ROBERT W. · August 3, 2026 · Grant37.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
OBX to Present Updated Data on Advanced Melanoma Trials
Obsidian Therapeutics announced that it will present new data from its Phase 1 study and the Phase 1/2 Agni‑01 multicenter trial of amsokigene autoleucel in patients whose advanced melanoma is resistant to immune‑checkpoint inhibitors. The update focuses on safety and early efficacy signals in this difficult‑to‑treat population. The presentation may provide further insight into the company's immunotherapy pipeline.
OBX to Present Updated Data on Advanced Melanoma Trials. Obsidian Therapeutics announced that it will present new data from its Phase 1 study and the Phase 1/2 Agni‑01 multicenter trial of amsokigene autoleucel in patients whose advanced melanoma is resistant to immune‑checkpoint inhibitors. The update focuses on safety and early efficacy signals in this difficult‑to‑treat population. The presentation may provide further insight into the company's immunotherapy pipeline.